Novo Nordisk obtains United States patent.
Novo Nordisk A/S (Bagsvaerd, Denmark) has patented insulin
precursors and insulin precursor analogs having a mini C-peptide
comprising at least one aromatic amino acid residue have an increased
folding stability. The insulin precursors and insulin precursor analogs
can be expressed in yeast in high yields and are preferably not more 15
amino acid residues in length. Also provided are polynucleotide sequences encoding the claimed precursors or precursor analogs, and
vectors and cell lines containing such polynucleotide sequences. (US